8 completed, 6 unknown, 3 active not recruiting, 2 recruiting. 11 Phase 2, 10 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Unknown 5, Completed 4, Recruiting 2 |
| Phase 1 | 10 | Unknown 4, Active not recruiting 3, Completed 1, Recruiting 1, Terminated 1 |
| Not applicable | 1 | Completed 1 |
Follow this condition Literature Review of Relapsed Non Hodgkin Lymphoma trials Research Report on Relapsed Non Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Completed | The First Affiliated Hospital of Soochow University | 100 | 2023-09-01 | 2026-06-03 | |
| CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). Mosunetuzumab, Polatuzumab, CAR-T Cell Therapy - Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma | Phase 2 | Recruiting | Lazaros Lekakis | 22 | 2022-12-14 | 2025-12-31 |
| Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma Loncastuximab tesirine, Venetoclax - Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | Paolo Caimi, MD | 23 | 2022-06-20 | 2026-06-05 |
| A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome VIP152, BTKi - Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Vincerx Pharma, Inc. | 6 | 2021-12-16 | 2023-11-18 |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) CB-010, Cyclophosphamide, Fludarabine - Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma | Phase 1 | Active not recruiting | Caribou Biosciences, Inc. | 72 | 2021-05-26 | 2026-10-19 |
| Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) autologous CD19-directed chimeric antigen receptor (CAR) T-cells - Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL | Phase 1 / Phase 2 | Recruiting | University of Alberta | 63 | 2021-03-03 | 2026-02-09 |
| A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity Anakinra, Axicabtagene Ciloleucel - Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 2 | Completed | Marcela V. Maus, M.D.,Ph.D. | 15 | 2020-10-01 | 2025-11-25 |
| A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma CD19/22 CART, Tislelizumab - Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 2 | Completed | The First Affiliated Hospital of Soochow University | 18 | 2020-08-01 | 2026-06-02 |
| Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell Lymphoma Relapsed Non Hodgkin Lymphoma, Refractory Lymphoma | Completed | National Taiwan University Hospital | 40 | 2020-06-01 | 2021-08-16 | |
| CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) CD19.CAR-aNKT cells - Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma | Phase 1 | Active not recruiting | Baylor College of Medicine | 13 | 2020-04-14 | 2026-07-13 |
| Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma azacitidine plus R-GDP - Diffuse Large B Cell Lymphoma, Relapsed Non Hodgkin Lymphoma | Phase 2 | Unknown | Seoul National University Hospital | 27 | 2018-12-01 | 2018-10-25 |
| MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin Rituximab, Fludarabine, Cyclophosphamide - Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Unknown | GC Cell Corporation | 9 | 2018-11-28 | 2020-07-28 |
| Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma Venetoclax - Relapsed Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Unknown | Nordic Lymphoma Group | 59 | 2018-07-01 | 2021-10-13 |
| Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma CAR19 T cells carrying cytoplasmic activated PD-1 - Relapsed Non Hodgkin Lymphoma | Phase 1 | Unknown | Henan Cancer Hospital | 15 | 2018-04-12 | 2018-05-30 |
| Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma Rituximab, Carboplatin, Cytarabine Injection - Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | La Raza Medical Center | 22 | 2018-04-05 | 2021-05-18 |
| CAR-T for R/R B-NHL CAR-T - Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 2 | Completed | The First Affiliated Hospital of Soochow University | 168 | 2017-06-01 | 2026-06-03 |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) GLIDE - Hematologic Cancer, Relapse Leukemia | Phase 1 / Phase 2 | Unknown | Ciusss de L'Est de l'Île de Montréal | 20 | 2017-02-06 | 2017-12-06 |
| Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma rituximab, ibritumomab tiuxetan, anti-thymocyte globulin - Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma | Phase 2 | Unknown | Joseph Tuscano | 20 | 2013-03-12 | 2022-11-30 |
| Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT Malignant Lymphoma, Relapsed Non Hodgkin Lymphoma | Completed | University Hospital, Brest | 100 | 2009-01-01 | 2020-07-09 | |
| Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHL Total body irradiation - Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Not applicable | Completed | Loyola University | 17 | 2006-06-01 | 2019-08-21 |
Lymphoma, Non-Hodgkin (20) · Lymphoma (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Recurrence (3) · Hodgkin Disease (2) · Lymphoma, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Cytokine Release Syndrome (1) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, B-Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1)
Hemic and Lymphatic Diseases (20) · Immune System Diseases (20) · Immunoproliferative Disorders (20) · Lymphatic Diseases (20) · Lymphoproliferative Disorders (20) · Neoplasms (20) · Neoplasms by Histologic Type (20) · Lymphoma (16) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Disease Attributes (4) · Hematologic Diseases (4) · Leukemia, Lymphoid (4) · Leukemia (3) · Lymphoma, B-Cell (2)
Rituximab (3) · Cyclophosphamide (2) · fludarabine (2) · venetoclax (2) · Antilymphocyte Serum (1) · Automobiles (1) · Azacitidine (1) · Carboplatin (1) · Cyclosporine (1) · Cytarabine (1) · Dexamethasone (1) · Filgrastim (1) · Immune Checkpoint Inhibitors (1) · Immunotherapy, Adoptive (1) · Interleukin 1 Receptor Antagonist Protein (1)
The First Affiliated Hospital of Soochow University (3) · Baylor College of Medicine (1) · Caribou Biosciences, Inc. (1) · Ciusss de L'Est de l'Île de Montréal (1) · GC Cell Corporation (1) · Henan Cancer Hospital (1) · Joseph Tuscano (1) · La Raza Medical Center (1) · Lazaros Lekakis (1) · Loyola University (1) · Marcela V. Maus, M.D.,Ph.D. (1) · National Taiwan University Hospital (1) · Nordic Lymphoma Group (1) · Paolo Caimi, MD (1) · Seoul National University Hospital (1)
United States (8) · China (4) · Canada (2) · South Korea (2) · Australia (1) · Denmark (1) · Finland (1) · Israel (1) · Mexico (1) · Norway (1) · Poland (1) · Sweden (1) · Taiwan (1)
Carlos Ramos, MD (1) · Cheng-Hong Tsai, MD, MSc, PhD (1) · Denis-Claude Roy, MD PhD (1) · Depei Wu (1) · Depei Wu, M.D. (1) · Dr. Michael P Chu, MD (1) · Joseph Tuscano (1) · Lazaros Lekakis, MD (1) · Mats Jerkeman (1) · Matt J Frigault, MD (1) · Paolo Caimi, MD (1) · Patrick Stiff, MD (1) · Silvy Lachance, MD (1)
PMID 31219975, PMID 31335321, PMID 34113569, PMID 34766217, PMID 35432352, PMID 36131934, PMID 37882668, PMID 38113470, PMID 39928957, PMID 40656663
2017 (1), P50CA126752 (1)